What to Ask Any Hormone or Weight Loss Clinic Before You Sign Up

A hormone clinic and a subscription hormone service can look identical online. Both have professional websites, reassuring language about safety and efficacy, and easy sign-up flows. The difference — whether a physician is actually making clinical decisions, whether your treatment is individualized to your biology, whether there is real medical accountability — is not visible from the homepage. It becomes visible only when you ask the right questions.

Here are the ten questions that separate a medical practice from a commercial subscription operation. Ask them before you sign up. The answers will tell you what you need to know.

The Ten Questions

1. Is a licensed physician reviewing my case before prescribing? Not a physician assistant following a protocol, not a nurse practitioner with limited autonomous prescribing authority, and not an algorithm. A physician whose license is on the record and whose name appears in your clinical documentation. If the answer is vague, that is the answer.

2. Will I have lab work before starting treatment? Hormone therapy without baseline labs is not medicine. It is a guess. Baseline estradiol, progesterone, FSH, testosterone, DHEA-S, and SHBG are standard components of a proper pre-treatment assessment. If labs are optional or not included, the treatment is not individualized.

3. How will my dose be individualized to my results? The answer should reference your specific lab values and how they map to dosing decisions. A non-answer — "our protocols are based on the latest research" — means the dose is standard, not yours.

4. How often will my labs be reviewed during treatment? At minimum, three and six months after starting. This is where adjustments happen, where problems get caught early, and where the clinical picture is updated. If there is no monitoring schedule, there is no clinical management — there is only a subscription.

5. What happens if my symptoms do not improve — who makes that call? There should be a physician who owns that question and has the clinical authority and information to answer it. If the answer is "contact customer support," you have your answer.

6. Can this practice decline to prescribe if I am not an appropriate candidate? If the answer is anything other than a clear yes, the clinical decision-making is compromised by a commercial incentive to maintain subscriptions.

7. Where does my medication come from? An FDA-regulated, licensed compounding pharmacy or a commercially approved pharmaceutical manufacturer. Not a fulfilment center that is not named or regulated. Ask for the pharmacy name and verify it is licensed in your state.

8. Can I speak with the prescribing physician directly? Not a patient coordinator. The physician. If the answer is no, that physician is not practicing medicine for you — they are providing a signature.

9. Is there an ongoing monitoring plan, or just refills? A monitoring plan means scheduled lab reviews, clinical check-ins, and explicit decision points where the treatment is assessed. Monthly refills with no clinical review is logistics, not care.

10. What happens if I have side effects — who manages that? A physician who knows your case and has the authority to adjust or discontinue treatment. Not a FAQ page.

IHA's BHRT and GLP-1 programs are designed to satisfy every one of these questions with a clear, specific answer. Physician-directed care means there is a clinician accountable for your treatment — not a platform that processes your subscription. Ask the questions. Then compare the answers.

The Questions Most Women Don't Know to Ask

The ten questions above represent the minimum standard for evaluating a hormone or weight loss clinic. But there are additional questions that most women don't think to ask — because they don't know what good looks like. Here are five more that separate good from excellent.

Does the practice maintain its own medical records, or am I just in an app? A legitimate medical practice maintains patient records that belong to the practice and are available to the patient. A subscription service often maintains records in a proprietary format that may not be accessible if the service changes or the subscription lapses. Ask for a summary of your medical record and see whether one can be provided.

What is the prescribing physician's specific training in hormone optimization? A physician who is a generalist, an urgent care doctor, or a gynaecologist by training and who has been added to a telehealth platform's prescribing roster is different from a physician who has specifically built expertise in hormone optimization and metabolic medicine. Ask what makes this physician specifically qualified for this area of practice.

What pharmacy fills my prescriptions? For compounded medications — which most bioidentical hormones are — the quality and safety of the compounding pharmacy matters. An FDA-regulated 503B outsourcing facility operates under pharmaceutical manufacturing standards. A 503A compounding pharmacy operates under different standards and varies significantly in quality. Know which category your pharmacy falls into.

What is the practice's approach to dose escalation? For GLP-1 therapy specifically, the pace of escalation is a direct determinant of side effect burden. A practice that pushes patients to higher doses faster to show results is not making clinical decisions — it is making commercial ones. A practice that escalates based on tolerability and clinical response is doing medicine.

What happens to my care if I need to pause treatment? Life happens: a surgery, a pregnancy, a medication change that requires a treatment pause. A real medical practice has a clinical protocol for managing pauses and resumptions. A subscription service has a cancellation flow. How a practice handles interruption tells you about the nature of the relationship it is building with patients.

Red Flags That Should End the Conversation

Some answers to the questions above are not ambiguous. These are the responses that should end your evaluation of a clinic immediately.

"We approve over 90 percent of applicants" or any similar statistic presented as a selling point. Clinical approval rates should not be a marketing metric. A practice that advertises high approval rates is not describing its clinical rigor. It is describing its commercial model.

No physician name in the prescribing documentation you receive. If you cannot identify by name the physician who authorized your prescription — and verify that they hold a valid license in your state — you do not have a treating physician. You have a signature.

Labs described as "optional" or available as an "upgrade." Baseline labs are not an upgrade. They are the minimum necessary to make individualized prescribing decisions. A practice that offers labs as an optional feature is telling you that its default is to prescribe without that information.

Customer service as the contact point for clinical questions. If you have a concern about your treatment and the correct contact is a customer service team rather than a clinical staff member — call that is answered by someone following a script rather than a nurse or physician — you are not receiving medical care. You are receiving a product with medical branding.

IHA's physician-directed program is built to provide clear, specific answers to every question above. The BHRT and GLP-1 therapy programs include comprehensive labs, individualized dosing, and structured monitoring as standard — not as premium features. The questions above are not a barrier. They are an invitation.

Applying the Framework to IHA Specifically

A checklist for evaluating any hormone or weight loss clinic is only as useful as the willingness to apply it honestly, including to the clinic doing the recommending. The questions in this post's framework deserve transparent answers as they apply to IHA's own practice — not marketing language, but the specific factual answers a real clinical practice should be able to provide without hesitation.

Who is the physician who will prescribe for me, and is that license verifiable? IHA operates with named, licensed physicians who carry individual prescribing responsibility. The prescribing physician for a given patient is identifiable, holds a valid medical license in the relevant state, and that license is verifiable through the state medical board's public license lookup. Telehealth licensure operates under interstate compacts for states that have adopted them and individual state licensing for others; IHA's clinical team maintains licensure coverage for the states in which they practice. If you ask IHA for the name and license number of the physician who will manage your care, that question will be answered with a specific name, not a reference to a clinical team.

What labs do you order, and when? For a BHRT program, the baseline panel includes estradiol, FSH, progesterone, total and free testosterone, SHBG, DHEA-S, complete metabolic panel, CBC, thyroid panel (TSH, free T3, free T4), fasting lipids, and fasting insulin. Follow-up labs at eight to twelve weeks include the full hormone panel to verify therapeutic levels and assess for appropriate dose calibration. Ongoing monitoring occurs at defined intervals — typically every six months for stable patients and more frequently following dose adjustments. The labs are ordered through standard reference laboratory networks and reviewed by the prescribing physician, not by an automated algorithm that generates a refill without clinical review.

What pharmacy fills my prescription? IHA sources compounded hormone prescriptions from registered 503B outsourcing facilities — facilities regulated under the FDA's DQSA framework, subject to cGMP standards, and required to conduct finished-product testing for potency, sterility, and stability. This is not a marketing claim; the specific facility name and its FDA registration status are verifiable by the patient through the FDA's public database of registered outsourcing facilities. For women who want to understand why the 503B distinction matters, the post on bioidentical versus synthetic hormones covers the pharmaceutical quality implications in detail.

What is the dose escalation approach? For GLP-1 programs, IHA starts at a low dose and titrates based on tolerability and clinical response, not a fixed schedule. A woman who is tolerating a starting dose without difficulty and showing appropriate metabolic response may stay at that dose longer than a standard titration would suggest, because the goal is the minimum effective dose rather than the maximum tolerated dose. For BHRT, the starting dose is calibrated to the clinical picture at baseline, with adjustment at the three-month visit based on both lab results and symptom response. Dose escalation decisions are made by the prescribing physician after reviewing labs — they are not automated.

What happens during treatment pauses? When a patient needs to pause treatment — due to a planned surgery, a change in medication, a medical event requiring evaluation, or any other clinical reason — IHA's protocol includes a clinical review of the pause indication, guidance on how to manage the interruption, and a defined pathway to resume. A patient who pauses treatment for thirty days does not restart at her prior dose without clinical reassessment; the restart is managed as a clinical decision, not an automatic renewal. This matters because physiological responses to dose gaps vary, and resuming at a prior dose after a significant pause carries risks that a responsible protocol addresses directly.

Where IHA is specifically strong is in the clinical architecture that makes each of these answers possible: a named physician with actual prescribing responsibility, a complete lab protocol reviewed by that physician, a 503B pharmacy source, and a clinical communication structure that handles between-appointment concerns through a clinical pathway rather than customer service. The framework was built this way because the alternative — the lab-optional, physician-distant, customer-service-dependent model described in the post on prescription farms — represents the specific failure modes that motivated IHA's design. If you want to evaluate IHA directly against the questions in this framework, contact the practice and ask them. The answers should be immediate, specific, and verifiable — and if they are not, that information is as useful as if they were.

The transparency represented by this self-evaluation is itself a clinical signal. A practice that can answer every question on the evaluation checklist specifically and verifiably — physician name, license number, lab protocol, pharmacy category, dose escalation approach, between-appointment clinical pathway — is demonstrating that it has built the infrastructure required to practice medicine rather than to process transactions. That infrastructure has costs: maintaining physician oversight, sourcing from quality-assured pharmacies, ordering and reviewing labs, staffing clinical communication pathways. Those costs are reflected in the program price. What they purchase is the difference between a clinical program that monitors your health while you are in it and a subscription service that ships a product until you cancel. For women evaluating whether that difference is worth the cost, the relevant comparison is not cost-per-month but value-per-outcome — and the outcomes associated with monitored, individualized, physician-supervised care are what the clinical evidence supports. The checklist is a way of verifying that a practice is actually delivering what the evidence requires. Apply it to IHA. Apply it to every other option you are considering. The answers will do the sorting.

Applying the Framework Before You Sign Anything

The ten questions that distinguish a medical practice from a subscription service are most valuable when they are used before a first payment is made, not afterward. The experience of discovering that a clinic does not have a specific physician managing your care — or does not have a monitoring protocol — or sends your questions to a customer service queue rather than a clinician — is far less costly as a pre-enrollment discovery than as a post-enrollment realization.

The friction of asking these questions directly should not deter you. A clinic that takes offense at clinical questions about its operations is providing useful information about how it would respond to clinical questions about your care. A clinic that answers them specifically and confidently, with details about the specific physician, the specific monitoring schedule, and the specific path to clinical support between appointments, is demonstrating the operational infrastructure that those answers describe.

IHA answers these questions directly because the practice is built around the clinical components they are evaluating. The physician-directed model at IHA is not a marketing claim; it is the structural basis of how the service operates. Applying the same due diligence that any important health decision warrants will identify that for any woman who takes the time to ask.

Using the Framework to Make a Final Decision

After applying the ten questions to any hormone or GLP-1 clinic you are evaluating, you will likely find that the clinics fall clearly into two categories: those that answer the questions specifically and confidently, and those that deflect, reframe, or simply cannot answer because the service does not include the components the questions are asking about. This is a useful sorting mechanism, and it should be applied before you make any financial commitment or begin any treatment.

The goal is not to find the cheapest option or the most convenient one — it is to find the option that is actually practicing medicine for your specific clinical case. The most convenient option that is not managing your care is not a better deal than the physician-directed option; it is a more expensive failure, because the months spent on a program that does not have the clinical infrastructure to produce real results are months during which the underlying condition continues to progress. Apply the framework to IHA with the same rigor you would apply to any other provider — you will find that it holds up to every question, and that the answers provide a meaningful basis for the trust that a good clinical relationship requires.